TaiGen Biopharmaceuticals Holdings Limited (TPEX:4157)
Taiwan · Delayed Price · Currency is TWD 9.03
-0.14 (-1.53%)
Sep 8, 2026, 12:48 PM CST
TPEX:4157 Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 6,528 | 9,539 | 8,219 | 10,911 | 11,505 | 11,039 | |
Market Cap Growth | -6.16% | 16.05% | -24.67% | -5.16% | 4.22% | -32.60% |
Enterprise Value | 5,624 | 8,758 | 7,222 | 10,169 | 10,545 | 10,032 |
Last Close Price | 9.17 | 13.40 | 11.45 | 15.20 | 16.05 | 15.40 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 42.48 | 211.13 | - | 79.80 | - | 14.23 |
Forward PE | - | 27.83 | 27.83 | 27.83 | 27.83 | 27.83 |
PS Ratio | 25.45 | 36.76 | 54.56 | 88.61 | 317.56 | 8.53 |
PB Ratio | 6.39 | 8.87 | 7.59 | 9.75 | 11.86 | 8.81 |
P/TBV Ratio | 6.64 | 9.06 | 7.68 | 9.87 | 11.86 | 8.81 |
P/FCF Ratio | 125.79 | 489.64 | - | 3055.51 | - | 17.84 |
P/OCF Ratio | 122.05 | 455.76 | - | 1462.83 | - | 17.55 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 21.93 | 33.75 | 47.94 | 82.59 | 291.05 | 7.75 |
EV/EBITDA Ratio | 60.00 | 119.88 | - | - | - | 11.03 |
EV/EBIT Ratio | 68.02 | 126.21 | - | - | - | 11.15 |
EV/FCF Ratio | 108.37 | 449.58 | - | 2847.73 | - | 16.21 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.01 | 0.05 | 0.05 | 0.07 | 0.04 | 0.04 |
Debt / EBITDA Ratio | 0.12 | 0.57 | - | - | - | 0.06 |
Debt / FCF Ratio | 0.22 | 2.53 | - | 20.92 | - | 0.09 |
Net Debt / Equity Ratio | -0.88 | -0.91 | -0.89 | -0.86 | -0.89 | -0.69 |
Net Debt / EBITDA Ratio | -11.29 | -13.38 | 8.45 | 5.85 | 3.22 | -0.96 |
Net Debt / FCF Ratio | -17.42 | -50.18 | 5.54 | -269.76 | 34.88 | -1.41 |
Asset Turnover | 0.24 | 0.22 | 0.13 | 0.11 | 0.03 | 1.33 |
Inventory Turnover | 0.28 | 0.31 | 0.42 | 0.46 | 0.23 | 0.78 |
Quick Ratio | 29.52 | 12.51 | 22.49 | 22.38 | 17.97 | 13.41 |
Current Ratio | 31.84 | 13.48 | 23.57 | 23.19 | 18.50 | 13.71 |
Return on Equity (ROE) | 15.55% | 4.19% | -3.51% | 13.09% | -21.33% | 91.47% |
Return on Assets (ROA) | 4.81% | 3.71% | -6.35% | -9.59% | -14.23% | 57.68% |
Return on Invested Capital (ROIC) | 69.99% | 49.94% | -88.22% | -125.41% | -112.72% | 311.53% |
Return on Capital Employed (ROCE) | 8.00% | 6.40% | -10.80% | -14.80% | -27.90% | 69.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 4, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.38% | 0.47% | -0.47% | 1.25% | -2.06% | 7.03% |
FCF Yield | 0.79% | 0.20% | -2.11% | 0.03% | -0.21% | 5.61% |
Buyback Yield / Dilution | 1.31% | 0.19% | -0.03% | -0.06% | 0.07% | -0.07% |